The development of the rotigotine transdermal patch. A historical perspective

Neurologic Clinics

Volumn 31, Issue 3 S, 2013, Pages

  Waters, Cheryl ^a  

^a Columbia University ^*  (United States)

Author keywords

Continuous delivery; Dopamine receptor agonist; Parkinson's disease; Rotigotine; Transdermal

Indexed keywords

AMANTADINE; BIPERIDEN; DOMPERIDONE; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE;

DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG STORAGE; HUMAN; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETINA DEGENERATION; REVIEW; SLOW RELEASE FORMULATION; TRANSDERMAL PATCH; UNIFIED PARKINSON DISEASE RATING SCALE;

CONTINUOUS DELIVERY; DOPAMINE RECEPTOR AGONIST; PARKINSON'S DISEASE; ROTIGOTINE; TRANSDERMAL;

ANIMALS; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; HUMANS; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH;

EID: 84881514504     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.04.012     Document Type: Review

References (83)

1. LeWitt P.A., Lyons K.E., Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007, 68(16):1262-1267.
2. Voon V., Fernagut P.O., Wickens J., et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009, 8(12):1140-1149.
3. LeWitt P.A. Levodopa for the treatment of Parkinson's disease. NEngl J Med 2008, 359(23):2468-2476.
4. Poewe W., Antonini A., Zijlmans J.C., et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 2010, 5:229-238.
5. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994, 17(Suppl 2):S32-S44.
6. Stocchi F., Jenner P., Obeso J.A. When do levodopa motor fluctuations first appear in Parkinson's disease?. Eur Neurol 2010, 63(5):257-266.
7. Chapuis S., Ouchchane L., Metz O., et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005, 20(2):224-230.
8. Pechevis M., Clarke C.E., Vieregge P., et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005, 12(12):956-963.
9. Calabresi P., Di Filippo M., Ghiglieri V., et al. Levodopa-induced dyskinesias inpatients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9(11):1106-1117.
10. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9(9):665-677.
11. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53(5):583-587.
12. Baronti F., Mouradian M.M., Davis T.L., et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992, 32(6):776-781.
13. Bibbiani F., Costantini L.C., Patel R., et al. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005, 192(1):73-78.
14. Blanchet P.J., Calon F., Martel J.C., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. JPharmacol Exp Ther 1995, 272(2):854-859.
15. Engber T.M., Susel Z., Juncos J.L., et al. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. EurJPharmacol 1989, 168(3):291-298.
16. Pfeiffer R.F. Apromising new technology for Parkinson's disease. Neurology 2005, 65(2 Suppl 1):S6-S10.
17. Jenner P. Anovel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 2005, 65(2 Suppl 1):S3-S5.
18. Van der Weide J., De Vries J.B., Tepper P.G., et al. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur J Pharmacol 1986, 125(2):273-282.
19. Van der Weide J., Tendijck M.E., Tepper P.G., et al. The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors. Eur J Pharmacol 1988, 146(2-3):319-326.
20. Belluzzi J.D., Domino E.F., May J.M., et al. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994, 9(2):147-154.
21. Loschmann P.A., Chong P.N., Nomoto M., et al. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur J Pharmacol 1989, 166(3):373-380.
22. Friedman D.J., Krause D.N., Duckles S.P. Complex prejunctional actions of the D2 dopamine agonists N-0923 and N-0924 in the rat tail artery. JPharmacol Exp Ther 1992, 260(2):568-575.
23. Scheller D., Ullmer C., Berkels R., et al. The invitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009, 379(1):73-86.
24. Millan M.J., Maiofiss L., Cussac D., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. JPharmacol Exp Ther 2002, 303(2):791-804.
25. Radad K., Gille G., Rausch W.D. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep 2005, 57(6):701-712.
26. Jenner P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003, 16(Suppl 1):S3-S7.
27. Joyce J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001, 90(2-3):231-259.
28. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997, 49(3):231-252.
29. Missale C., Nash S.R., Robinson S.W., et al. Dopamine receptors: from structure to function. Physiol Rev 1998, 78(1):189-225.
30. Robertson H.A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 1992, 15(6):201-206.
31. Vermeulen R.J., Drukarch B., Sahadat M.C., et al. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. Mov Disord 1994, 9(6):664-672.
32. Barone P. Neurotransmission in Parkinson's disease: beyond dopamine. EurJNeurol 2010, 17(3):364-376.
33. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8(5):464-474.
34. Fox S.H., Brotchie J.M., Lang A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008, 7(10):927-938.
35. Lucki I., Singh A., Kreiss D.S. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev 1994, 18(1):85-95.
36. Savitz J., Lucki I., Drevets W.C. 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 2009, 88(1):17-31.
37. Nicholson S.L., Brotchie J.M. 5-Hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002, 9(Suppl 3):1-6.
38. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011, 17(1):58-65.
39. Henry B., Fox S.H., Peggs D., et al. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999, 14(5):744-753.
40. Schmid D.A., Wichniak A., Uhr M., et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006, 31(4):832-844.
41. Kehr J., Hu X.J., Goiny M., et al. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. JNeural Transm 2007, 114(8):1027-1031.
42. Schmidt W.J., Lebsanft H., Heindl M., et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. JNeural Transm 2008, 115(10):1385-1392.
43. Stockwell K.A., Scheller D., Rose S., et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol 2009, 219(2):533-542.
44. European Medicines Agency. Neupro: EPAR Product information. Available at:. Accessed May 15, 2013. http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000626/human_med_000926.jsp&mid=WC0b01ac058001d124.
45. European Medicines Agency. Neupro: EPAR Scientific discussion. Available at: Accessed October 25, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000626/WC500026394.pdf.
46. Elmer L.W., Surmann E., Boroojerdi B., et al. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012, 18(5):488-493.
47. Jankovic J., Watts R.L., Martin W., et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007, 64(5):676-682.
48. Parkinson Study Group Acontrolled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003, 60(12):1721-1728.
49. Trenkwalder C., Kies B., Rudzinska M., et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011, 26(1):90-99.
50. Watts R.L., Jankovic J., Waters C., et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68(4):272-276.
51. Swart P.J., De Zeeuw R.A. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 1992, 47(8):613-615.
52. Swart P.J., de Zeeuw R.A. Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. JPharm Sci 1993, 82(2):200-203.
53. Calabrese V.P., Lloyd K.A., Brancazio P., et al. N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov Disord 1998, 13(5):768-774.
54. Hutton J.T., Metman L.V., Chase T.N., et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001, 16(3):459-463.
55. Metman L.V., Gillespie M., Farmer C., et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001, 24(3):163-169.
56. Cawello W., Braun M., Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009, 37(10):2055-2060.
57. Cawello W., Wolff H.M., Meuling W.J., et al. Transdermal administration of radiolabelled [14C]rotigotine by a patch formulation: a mass balance trial. Clin Pharm 2007, 46(10):851-857.
58. Hansen K., Braun M., Horstmann R. Low drug-drug interaction potential of rotigotine. JClin Pharmacol 2005, 45. [abstract 1091].
59. Swart P.J., Jansman F.G., Drenth B.F., et al. Impact of structural differences on theinvitro glucuronidation kinetics of potentially dopaminergic hydroxy-2-aminotetralins and naphthoxazines using rat and human liver microsomes. Pharmacol Toxicol 1991, 68(3):215-219.
60. Swart P.J., Oelen W.E., Bruins A.P., et al. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. JAnal Toxicol 1994, 18(2):71-77.
61. Baldwin C.M., Keating G.M. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. CNS Drugs 2007, 21(12):1039-1055.
62. Paudel K.S., Milewski M., Swadley C.L., et al. Challenges and opportunities in dermal/transdermal delivery. Ther Deliv 2010, 1(1):109-131.
63. Wolff HM, Seiffert T, Boddenberg A, etal. Drug release characteristics of rotigotine transdermal system. Presented at the 33rd Annual Meeting, Exposition of the Controlled Release Society, Vienna, Austria, July 22-26, 2006.
64. Braun M., Cawello W., Poole K., et al. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005, 12(Suppl 2):96. [abstract P1245].
65. Elshoff J.P., Braun M., Andreas J.O., et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012, 34(4):966-978.
66. Whitesides J., Cawello W., Woltering F., et al. Stable plasma levels of rotigotine following transdermal patch removal and new patch application during long-term treatment of patients with advanced Parkinson's disease. Neurology 2011, 76(Suppl 4):A275.
67. Braun M., Cawello W., Boekens H., et al. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009, 67(2):209-215.
68. Braun M., Cawello W., Andreas J.O., et al. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. JClin Pharmacol 2009, 49(9):1047-1055.
69. Rascol O., Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009, 10(4):677-691.
70. Cawello W., Braun M., Horstmann R., et al. Pharmacokinetics, safety and tolerability of rotigotine after transdermal patch administration in Japanese and Caucasian healthy subjects. Mov Disord 2006, 21(Suppl 15):S547-S548. [abstract P9802].
71. Cawello W., Braun M., Horstmann R. Impact of moderate impairment of hepaticfunction on the steady-state pharmacokinetics of transdermal rotigotine. Eur J Neurol 2007, 14(Suppl 1):199. [abstract P2149].
72. Cawello W., Ahrweiler S., Sulowicz W., et al. Single-dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2011, 10.1111/j.1365-2125.2011.04053.x.
73. Berner B., John V.A. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharm 1994, 26(2):121-134.
74. Christie J. The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia. Palliat Med 2007, 21(2):163-164.
75. Makaroff L., Gunn A., Gervasoni C., et al. Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database. JParkinsons Dis 2011, 1(1):65-74.
76. Pepper P.V., Goldstein M.K. Postoperative complications in Parkinson's disease. JAm Geriatr Soc 1999, 47(8):967-972.
77. Barber M., Stewart D., Gr D., et al. Patient and carer perception of the management of Parkinson's disease after surgery. Age Ageing 2001, 30(2):171-172.
78. Frucht S.J. Movement disorder emergencies in the perioperative period. Neurol Clin 2004, 22(2):379-387.
79. Wüllner U., Kassubek J., Odin P., et al. Transdermal rotigotine for the perioperative management of Parkinson's disease. JNeural Transm 2010, 117(7):855-859.
80. Korczyn A.D., Reichmann H., Boroojerdi B., et al. Rotigotine transdermal system for perioperative administration. JNeural Transm 2007, 114(2):219-221.
81. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., et al. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010, 67(1):64-70.
82. Chaudhuri K.R. Crystallisation within transdermal rotigotine patch: is there cause for concern?. Expert Opin Drug Deliv 2008, 5(11):1169-1171.
83. US National Institutes of Health Study in healthy volunteers to prove that two different formulations of rotigotine patches deliver equivalent drug amount to the body 2011, National Library of Medicine, Bethesda (MD), Available at:, Accessed May 15, 2013. http://clinicaltrials.gov/ct2/show/NCT01059903.